JP2017527602A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527602A5
JP2017527602A5 JP2017515074A JP2017515074A JP2017527602A5 JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5 JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5
Authority
JP
Japan
Prior art keywords
piperidine
piperidin
carboxylic acid
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515074A
Other languages
English (en)
Japanese (ja)
Other versions
JP6678656B2 (ja
JP2017527602A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/057219 external-priority patent/WO2016042536A1/en
Publication of JP2017527602A publication Critical patent/JP2017527602A/ja
Publication of JP2017527602A5 publication Critical patent/JP2017527602A5/ja
Priority to JP2020035272A priority Critical patent/JP6908747B2/ja
Application granted granted Critical
Publication of JP6678656B2 publication Critical patent/JP6678656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017515074A 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 Active JP6678656B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020035272A JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
US62/052,537 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035272A Division JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2017527602A JP2017527602A (ja) 2017-09-21
JP2017527602A5 true JP2017527602A5 (enExample) 2018-10-25
JP6678656B2 JP6678656B2 (ja) 2020-04-08

Family

ID=54238488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515074A Active JP6678656B2 (ja) 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Country Status (21)

Country Link
US (2) US9938260B2 (enExample)
EP (1) EP3194384A1 (enExample)
JP (3) JP6678656B2 (enExample)
KR (1) KR20170054508A (enExample)
CN (1) CN106687456B (enExample)
AU (1) AU2015319724B2 (enExample)
BR (1) BR112017005660A2 (enExample)
CA (1) CA2961745A1 (enExample)
CL (1) CL2017000640A1 (enExample)
CO (1) CO2017002506A2 (enExample)
CR (1) CR20170102A (enExample)
DO (1) DOP2017000073A (enExample)
EA (1) EA033697B1 (enExample)
IL (1) IL251094A0 (enExample)
MA (1) MA40583A (enExample)
MX (1) MX2017003621A (enExample)
PE (1) PE20170937A1 (enExample)
PH (1) PH12017500481A1 (enExample)
SG (1) SG11201701915TA (enExample)
WO (1) WO2016042536A1 (enExample)
ZA (1) ZA201701835B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112055584A (zh) 2018-04-30 2020-12-08 拜耳公司 sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
JP5411703B2 (ja) * 2006-11-09 2014-02-12 アルコン リサーチ, リミテッド 薬物送達のための水不溶性ポリマーマトリクス
PE20091258A1 (es) * 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Similar Documents

Publication Publication Date Title
JP2014513110A5 (enExample)
JP2016525076A5 (enExample)
JP2019528307A5 (enExample)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019505594A5 (enExample)
JP2018519323A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2003521537A5 (enExample)
JP2016520131A5 (enExample)
JP2019535672A5 (enExample)
JP2013510125A5 (enExample)
JP2017528487A5 (enExample)
JP2016514719A5 (enExample)
JP2017504611A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2015508749A5 (enExample)
JP2014511891A5 (enExample)
JP2013540823A5 (enExample)
JP2009515814A5 (enExample)
JP2015524472A5 (enExample)
FI3555076T3 (fi) Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja
JP2015514806A5 (enExample)
JP2004511469A5 (enExample)
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
RU2013132930A (ru) Производное пиразола